Watch for Vivjoa, a New Oral Rx for Vaginal Yeast Infections
September 2022
New Rx Vivjoa (oteseconazole) will be the first med approved for recurrent vaginal yeast infections.
Flag any new Rxs for...so the pharmacist can verify that therapy is appropriate.
This oral med is only for patients with 3 or more vaginal yeast infections per year who are postmenopausal or permanently infertile.Practical advice for a better career, with unlimited access to CE
Pharmacy Technician's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 120+ CE courses, including the popular CE-in-the-Letter
- Helpful, in-depth Technician Tutorials
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote